Tomasz M. Beer, M.D., F.A.C.P.

Head Shot of Tomasz Beer
click here
503 494-6594


Dr. Beer’s major research interests include clinical trials, preclinical investigation and risk factors in prostate cancer. His program investigates a broad range of novel agents for prostate cancer, including immune therapies, nutritional supplements, hormonal agents, chemotherapy drugs and target biologic drugs that seek to exploit prostate cancer’s unique vulnerabilities.

Dr. Beer’s clinical research program is tightly linked with laboratory investigations designed to reveal new treatment targets and strategies.

Summary of Current Research

Special Interests:Hematology and Medical OncologyProstate Cancer

Selected Publications

"Resistance training reduces disability in prostate cancer survivors on androgen deprivation therapy: Evidence from a randomized controlled trial," Archives of Physical Medicine and Rehabilitation (Vol: 96, Issue: 1, Page 7-14) - 2015

"A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer," Investigational New Drugs - 2014

"Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes," PLoS ONE (Vol: 9, Issue: 9, ) - 2014

"Enzalutamide in metastatic prostate cancer before chemotherapy," New England Journal of Medicine (Vol: 371, Issue: 5, Page 424-433) - 2014

"Feasibility, acceptability and findings from a pilot randomized controlled intervention study on the impact of a book designed to inform patients about cancer clinical trials," Journal of Cancer Education (Vol: 29, Issue: 1, Page 181-187) - 2014


OHSU Knight Cancer Institute

Visit Our Site

For Healthcare Professionals


  Email Tomasz Beer

503 494-6594

Memberships & Associations

American College of Physicians Oregon Medical Association American Society of Clinical Oncology American Society of Hematology American Association for Cancer Research Southwest Oncology Group American Urological Association Radiation Therapy Oncology Group